ADP-ribosyl cyclase and ryanodine receptor activity contribute to basal renal vasomotor tone and agonist-induced renal vasoconstriction in vivo

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 4, 2007, Pages

  Thai, Tiffany L ^a,b   Fellner, Susan K ^a   Arendshorst, William J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

CD38; FK506; Intracellular calcium; L type calcium channels; Vascular smooth muscle

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; ANGIOTENSIN II; CALCIUM CHANNEL; NICOTINAMIDE; RUTHENIUM RED; RYANODINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; IN VIVO STUDY; KIDNEY CIRCULATION; KIDNEY FUNCTION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASOMOTOR REFLEX;

EID: 35348884892     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00483.2006     Document Type: Article

References (65)

1. 2+ release from intracellular stores in astrocytes via cyclic ADP ribose-mediated activation of ryanodine receptors. Cell Calcium 39: 95-100, 2006.
2. Arendshorst WJ, Navar LG. Renal circulation and glomerular hemodynamics. In: Diseases of the Kidney and Urinary Tract, edited by Schrier RW. Philadelphia, PA: Lippincott Williams and Wilkins, 2006, p. 59-108.
3. Azevedo LC, Janiszewski M, Soriano FG, Laurindo FR. Redox mechanisms of vascular cell dysfunction in sepsis. Endocr Metab Immune Disord Drug Targets 6: 159-164, 2006.
4. Bagnis C, Deray G, Dubois M, Adabra Y, Jacquiaud C, Jaudon MC, Jacobs C. Comparative acute nephrotoxicity of FK-506 and ciclosporin in an isolated in situ autoperfused rat kidney model. Am J Nephrol 17: 17-24, 1997.
5. Beers KW, Chini EN, Lee HC, Dousa TP. Metabolism of cyclic ADP-ribose in opossum kidney renal epithelial cells. Am J Physiol Cell Physiol 268: C741-C746, 1995.
6. Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 57: 419-434, 1976.
7. Boffa JJ, Just A, Coffman TM, Arendshorst WJ. Thromboxane receptor mediates renal vasoconstriction and contributes to acute renal failure in endotoxemic mice. J Am Soc Nephrol 15: 2358-2365, 2004.
8. 3 and ryanodine receptor activation in vascular myocytes. Am J Physiol Cell Physiol 277: C139-C151, 1999.
9. Bruzzone S, De Flora A, Usai C, Graeff R, Lee HC. Cyclic ADP-ribose is a second messenger in the lipopolysaccharide-stimulated proliferation of human peripheral blood mononuclear cells. Biochem J 375: 395-403, 2003.
10. Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol Renal Fluid Electrolyte Physiol 256: F1015-F1020, 1989.
11. Chelu MG, Danila CI, Gilman CP, Hamilton SL. Regulation of ryanodine receptors by FK506 binding proteins. Trends Cardiovasc Med 14: 227-234, 2004.
12. Chini EN, Klener PJ, Beers KW, Chini CC, Grande JP, Dousa TP. Cyclic ADP-ribose metabolism in rat kidney: high capacity for synthesis in glomeruli. Kidney Int 51: 1500-1506, 1997.
13. Cibulsky SM, Sather WA. Block by ruthenium red of cloned neuronal voltage-gated calcium channels. J Pharmacol Exp Ther 289: 1447-1453, 1999.
14. 2+ influx. EMBO J 22: 4337-4345, 2003.
15. + channels on rat renal arteriolar responses to depolarizing agonists. Am J Physiol Renal Physiol 280: F583-F591, 2001.
16. 2+ signaling in afferent arterioles. Am J Physiol Renal Physiol 292: F175-F184, 2007.
17. 2+ release in preglomerular arterioles. Am J Physiol Renal Physiol 292: F1568-F1572, 2007.
18. 2+ signaling in afferent arterioles. Am J Physiol Renal Physiol 289: F1012-F1019, 2005.
19. 2+ signaling in rat afferent arterioles: stimulation of cyclic ADP ribose and IP3 pathways. Am J Physiol Renal Physiol 288: F785-F791, 2005.
20. Fellner SK, Arendshorst WJ. Endothelin A and B receptors of preglomerular vascular smooth muscle cells. Kidney Int 65: 1810-1817, 2004.
21. Fellner SK, Parker L. Endothelin-1, superoxide and adeninediphosphate ribose cyclase in shark vascular smooth muscle. J Exp Biol 208: 1045-1052, 2005.
22. 2+ oscillations and mesangial cell contraction. Kidney Int 70: 130-138, 2006.
23. Fleming JT, Parekh N, Steinhausen M. Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol Renal Fluid Electrolyte Physiol 253: F1157-F1163, 1987.
24. 2+ release by M1 muscarinic receptor activation in coronary arterial smooth muscle. J Vasc Res 40: 28-36, 2003.
25. Geiger J, Zou AP, Campbell WB, Li PL. Inhibition of cADP-ribose formation produces vasodilation in bovine coronary arteries. Hypertension 35: 397-402, 2000.
26. Gochuico BR, Zhang J, Ma BY, Marshak-Rothstein A, Fine A. TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol 278: L1045-L1050, 2000.
27. Hill-Eubanks DC, Gomez MF, Stevenson AS, Nelson MT. NFAT regulation in smooth muscle. Trends Cardiovasc Med 13: 56-62, 2003.
28. Hirst DG, Kennovin GD, Flitney FW. The radiosensitizer nicotinamide inhibits arterial vasoconstriction. Br J Radiol 67: 795-799, 1994.
29. 2+-permeable pore of the calcium release channel. J Biol Chem 262: 16636-16643, 1987.
30. Inscho EW, Cook AK, Mui V, Imig JD. Calcium mobilization contributes to pressure-mediated afferent arteriolar vasoconstriction. Hypertension 31: 421-428, 1998.
31. A receptors. Am J Physiol Renal Physiol 286: F660-F668, 2004.
32. + into a calcium-mobilizing metabolite. Cell Regul 2: 203-209, 1991.
33. Li N, Teggatz EG, Li PL, Allaire R, Zou AP. Formation and actions of cyclic ADP-ribose in renal microvessels. Microvasc Res 60: 149-159, 2000.
34. Liang M, Chini EN, Cheng J, Dousa TP. Synthesis of NAADP and cADPR in Mitochondria. Arch Biochem Biophys 371: 317-325, 1999.
35. 2+ entry. Circ Res 87: 551-557, 2000.
36. 2+ uptake into the sarcoplasmic reticulum. Circ Res 89: 614-622, 2001.
37. Ma J. Block by ruthenium red of the ryanodine-activated calcium release channel of skeletal muscle. J Gen Physiol 102: 1031-1056, 1993.
38. Migaud ME, Pederick RL, Bailey VC, Potter BV. Probing Aplysia californica adenosine 5′-diphosphate ribosyl cyclase for substrate binding requirements: design of potent inhibitors. Biochemistry 38: 9105-9114, 1999.
39. Mitsui-Saito M, Kato I, Takasawa S, Okamoto H, Yanagisawa T. CD38 gene disruption inhibits the contraction induced by alpha-adrenoceptor stimulation in mouse aorta. J Vet Med Sci 65: 1325-1330, 2003.
40. Morita K, Kitayama S, Dohi T. Stimulation of cyclic ADP-ribose synthesis by acetylcholine and its role in catecholamine release in bovine adrenal chromaffin cells. J Biol Chem 272: 21002-21009, 1997.
41. Myres BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 37: 101-110, 1975.
42. Namazi MR. Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB J 17: 1377-1379, 2003.
43. Nishimura Y, Tanaka T. Calcium-dependent activation of nuclear factor regulated by interleukin 3/adenovirus E4 promoter-binding protein gene expression by calcineurin/nuclear factor of activated T cells and calcium/calmodulin-dependent protein kinase signaling. J Biol Chem 276: 19921-8, 2001.
44. 2+ from islet microsomes. J Biol Chem 272: 3133-3136, 1997.
45. Partida-Sanchez S, Cockayne DA, Monard S, Jacobson EL, Oppenheimer N, Garvy B, Kusser K, Goodrich S, Howard M, Harmsen A, Randall TD, Lund FE. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med 7: 1209-1216, 2001.
46. Peters DH, Fitton A, Plosker GL, Faulds Tacrolimus D. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46: 746-794, 1993.
47. Ruan X, Arendshorst WJ. Calcium entry and mobilization signaling pathways in ANG II-induced renal vasoconstriction in vivo. Am J Physiol Renal Fluid Electrolyte Physiol 270: F398-F405, 1996.
48. Salomonsson M, Sorensen CM, Arendshorst WJ, Steendahl J, Holstein-Rathlou NH. Calcium handling in afferent arterioles. Acta Physiol Scand 181: 421-429, 2004.
49. Salomonsson M, Arendshorst WJ. Calcium recruitment in renal vasculature: NE effects on blood flow and cytosolic calcium concentration. Am J Physiol Renal Physiol 276: F700-F710, 1999.
50. Sanz E, Monge L, Fernandez N, Climent B, Dieguez G, Garcia-Villalon AL. Mechanisms of relaxation by urocortin in renal arteries from male and female rats. Br J Pharmacol 140: 1003-1007, 2003.
51. Schuber F, Lund FE. Structure and enzymology of ADP-ribosyl cyclases: conserved enzymes that produce multiple calcium mobilizing metabolites. Curr Mol Med 4: 249-261, 2004.
52. Schwertfeger E, Wehrens J, Oberhauser V, Katzenwadel A, Rump LC. Contractile effects of tacrolimus in human and rat isolated renal arteries. J Auton Pharmacol 21: 205-210, 2001.
53. Sethi JK, Empson RM, Galione A. Nicotinamide inhibits cyclic ADP-ribose-mediated calcium signalling in sea urchin eggs. Biochem J 319: 613-7, 1996.
54. 2+-release channel. Circ Res 75: 596-600, 1994.
55. Steiner RW, Tucker BJ, Blantz RC. Glomerular hemodynamics in rats with chronic sodium depletion. Effect of saralasin. J Clin Invest 64: 503-512, 1979.
56. Steinhausen M, Ballantyne D, Fretschner M, Hoffend J, Parekh N. Different responses of cortical and juxtamedullary arterioles to norepinephrine and angiotensin II. Kidney Int 30: S55-S59, 1990.
57. 2+ signaling. J Biol Chem 276: 15018-15024, 2001.
58. Szabo C. Pathophysiological aspects of cellular pyridine nucleotide metabolism: focus on the vascular endothelium. Acta Physiol Hung 90: 175-193, 2003.
59. Takeda Y, Miyamori I, Furukawa K, Inaba S, Mabuchi H. Mechanisms of FK 506 induced hypertension in the rat. Hypertension 33: 130-136, 1999.
60. Talesnik J, Labelle S. Enhancement of metabolic coronary vasodilatation by nicotinic acid or amide. Pharmacol Res Commun 16: 253-263, 2006.
61. Tang WX, Chen YF, Zou AP, Campbell WB, Li PL. Role of FKBP12.6 in cADPR-induced activation of reconstituted ryanodine receptors from arterial smooth muscle. Am J Physiol Heart Circ Physiol 282: H1304-H1310, 2002.
62. Watarai Y, Morita K, Shimoda N, Miura M, Yoshioka M, Togashi H, Nonomura K, Koyanagi T. Effect of tacrolimus and cyclosporine on renal microcirculation and nitric oxide production. Transplant Proc 36: 2130-2132, 2004.
63. Woon EC, Threadgill MD. Poly(ADP-ribose)polymerase inhibition-where now? Curr Med Chem 12: 2373-2392, 2005.
64. + channels in rat pituitary GH3 cells. J Pharmacol Exp Ther 290: 998-1005, 1999.
65. 2+ mobilizing second messenger - cyclic ADP-ribose. J Cell Mol Med 10: 407-422, 2006.